Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Hettinga, Awt Konings, H. Kampinga (1997)
Reduction of cellular cisplatin resistance by hyperthermia--a review.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 13 5
I. Königsrainer, P. Horvath, F. Struller, E. Grischke, D. Wallwiener, A. Königsrainer, S. Beckert (2014)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experienceLangenbeck's Archives of Surgery, 399
S. Urien, F. Lokiec (2004)
Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.British journal of clinical pharmacology, 57 6
P. Cashin, H. Ehrsson, I. Wallin, P. Nygren, H. Mahteme (2012)
Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosisEuropean Journal of Clinical Pharmacology, 69
M. Takemoto, M. Kuroda, M. Urano, Y. Nishimura, S. Kawasaki, H. Kato, Y. Okumura, S. Akaki, S. Kanazawa, J. Asaumi, I. Joja, Y. Hiraki (2003)
The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumoursInternational Journal of Hyperthermia, 19
Peter Burdon, Coralie Martin, S. Rankin (2008)
Migration across the sinusoidal endothelium regulates neutrophil mobilization in response to ELR + CXC chemokinesBritish Journal of Haematology, 142
Feifan Xie, P. Colin, J. Bocxlaer (2017)
Zwitterionic hydrophilic interaction liquid chromatography-tandem mass spectrometry with HybridSPE-precipitation for the determination of intact cisplatin in human plasma.Talanta, 174
N. Nagai, H. Ogata (1997)
Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivoCancer Chemotherapy and Pharmacology, 40
B. Royer, V. Jullien, E. Guardiola, B. Heyd, B. Chauffert, J. Kantelip, X. Pivot (2009)
Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative AdministrationClinical Pharmacokinetics, 48
Neil Evans, S. Cheung, James Yates (2018)
Structural identifiability for mathematical pharmacology: models of myelosuppressionJournal of Pharmacokinetics and Pharmacodynamics, 45
E. Cotte, O. Colomban, J. Guitton, B. Tranchand, Nawel Bakrin, F. Gilly, O. Glehen, M. Tod (2011)
Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Hyperthermic Intraperitoneal Chemotherapy Using a Closed Abdominal ProcedureThe Journal of Clinical Pharmacology, 51
P. Sugarbaker (1995)
Peritonectomy ProceduresAnnals of Surgery, 221
K. Fujiwara, D. Armstrong, M. Morgan, M. Markman (2006)
Principles and practice of intraperitoneal chemotherapy for ovarian cancerInternational Journal of Gynecologic Cancer, 17
Emilie Henin, Benoit You, E. Vancutsem, Paulo Hoff, Jim Cassidy, Chris Twelves, K. Zuideveld, Florin Sirzén, C. Dartois, Gilles Freyer, Michel Tod, Pascal Girard (2009)
A Dynamic Model of Hand‐and‐Foot Syndrome in Patients Receiving CapecitabineClinical Pharmacology & Therapeutics, 85
P. Specenier, T. Ciuleanu, J. Latz, L. Musib, C. Darstein, J. Vermorken (2009)
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patientsCancer Chemotherapy and Pharmacology, 64
W. Driel, C. Lok, V. Verwaal, G. Sonke (2015)
The Role of Hyperthermic Intraperitoneal Intraoperative Chemotherapy in Ovarian CancerCurrent Treatment Options in Oncology, 16
M. Tummala, S. Alagarsamy, W. Mcguire (2008)
Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?Expert Review of Anticancer Therapy, 8
B. Royer, E. Kalbacher, S. Onteniente, V. Jullien, D. Montange, S. Piédoux, A. Thiery-Vuillemin, D. Delroeux, S. Pili-Floury, E. Guardiola, M. Combe, P. Muret, V. Nerich, B. Heyd, B. Chauffert, J. Kantelip, X. Pivot (2011)
Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic studyBritish Journal of Cancer, 106
E. Bree, P. Theodoropoulos, H. Rosing, J. Michalakis, J. Romanos, J. Beijnen, D. Tsiftsis (2006)
Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside.Cancer treatment reviews, 32 6
P. O'dwyer, J. Stevenson, Steven Johnson (2012)
Clinical Pharmacokinetics and Administration of Established Platinum DrugsDrugs, 59
Enikő Borbás, B. Sinkó, Oksana Tsinman, K. Tsinman, Éva Kiserdei, B. Démuth, A. Balogh, B. Bodák, A. Domokos, Gergő Dargó, G. Balogh, Z. Nagy (2016)
Investigation and Mathematical Description of the Real Driving Force of Passive Transport of Drug Molecules from Supersaturated Solutions.Molecular pharmaceutics, 13 11
L. Sheiner (1994)
A new approach to the analysis of analgesic drug trials, illustrated with bromfenac dataClinical Pharmacology & Therapeutics, 56
C. Summers, S. Rankin, A. Condliffe, N. Singh, A. Peters, E. Chilvers (2010)
Neutrophil kinetics in health and diseaseTrends in Immunology, 31
P. Sugarbaker (1996)
Peritonectomy procedures.Cancer treatment and research, 82
W. Driel, S. Koole, K. Sikorska, J. Leeuwen, H. Schreuder, R. Hermans, I. Hingh, J. Velden, H. Arts, L. Massuger, A. Aalbers, V. Verwaal, J. Kieffer, K. Vijver, H. Tinteren, N. Aaronson, G. Sonke (2018)
Hyperthermic Intraperitoneal Chemotherapy in Ovarian CancerThe New England Journal of Medicine, 378
F. Farris, F. King, R. Dedrick, C. Litterst (1985)
Physiological model for the pharmacokinetics ofcis-dichlorodiammineplatinum(II) (DDP) in the tumored ratJournal of Pharmacokinetics and Biopharmaceutics, 13
K. Polom, G. Roviello, D. Generali, L. Marano, R. Petrioli, S. Marsili, Edda Caputo, D. Marrelli, F. Roviello (2016)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancerInternational Journal of Hyperthermia, 32
M. Joerger, A. Huitema, D. Richel, C. Dittrich, N. Pavlidis, E. Briasoulis, J. Vermorken, E. Strocchi, A. Martoni, R. Sorio, H. Sleeboom, M. Izquierdo, D. Jodrell, H. Calvert, A. Boddy, H. Hollema, R. Féty, W. Vijgh, G. Hempel, E. Chatelut, M. Karlsson, J. Wilkins, B. Tranchand, A. Schrijvers, C. Twelves, J. Beijnen, J. Schellens (2007)
Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development GroupClinical Cancer Research, 13
K. Hanada, Kazuyuki Nishijima, Hiroyasu Ogata, Shinji Atagi, Masaaki Kawahara (2001)
Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum.Japanese journal of clinical oncology, 31 5
Charlotte Carlier, B. Laforce, Stijn Malderen, F. Gremonprez, R. Tucoulou, J. Villanova, O. Wever, L. Vincze, F. Vanhaecke, W. Ceelen (2016)
Nanoscopic tumor tissue distribution of platinum after intraperitoneal administration in a xenograft model of ovarian cancer.Journal of pharmaceutical and biomedical analysis, 131
E. Bree, C. Helm (2012)
Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical dataExpert Review of Anticancer Therapy, 12
B. Royer, E. Guardiola, E. Polycarpe, G. Hoizey, D. Delroeux, M. Combe, L. Chaigneau, E. Samain, B. Chauffert, B. Heyd, J. Kantelip, X. Pivot (2005)
Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein bindingAnti-Cancer Drugs, 16
I. Alvovsky, V. Bespalov, G. Kireeva (2018)
Cisplatin in NIPEC or HIPEC?Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 8
E. Schindler, M. Karlsson (2017)
A Minimal Continuous-Time Markov Pharmacometric ModelThe AAPS Journal, 19
T. Batista, Levon Filho, C. Leão (2016)
Exploring flow rate selection in HIPEC procedures.Revista do Colegio Brasileiro de Cirurgioes, 43 6
K. Hanada, K. Asano, T. Nishimura, Tomomi Chimata, Yusuke Matsuo, Maki Tsuchiya, H. Ogata (2008)
Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in ratsJournal of Pharmacy and Pharmacology, 60
Karri Barabas, R. Milner, D. Lurie, C. Adin (2008)
Cisplatin: a review of toxicities and therapeutic applications.Veterinary and comparative oncology, 6 1
X. Yao, K. Panichpisal, N. Kurtzman, K. Nugent (2007)
Cisplatin Nephrotoxicity: A ReviewThe American Journal of the Medical Sciences, 334
N. Nagai, M. Kinoshita, H. Ogata, D. Tsujino, Y. Wada, K. Someya, T. Ohno, K. Masuhara, Yoshio Tanaka, Katsuhiko Kato, Haruki Nagai, A. Yokoyama, Y. Kurita (1996)
Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patientsCancer Chemotherapy and Pharmacology, 39
O. Saux, E. Decullier, G. Freyer, O. Glehen, N. Bakrin (2018)
Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)International Journal of Hyperthermia, 35
L. Friberg, A. Henningsson, H. Maas, L. Nguyen, M. Karlsson (2002)
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 24
C. Perez-Ruixo, B. Valenzuela, J. Peris, P. Bretcha-Boix, V. Escudero-Ortiz, J. Farré-Alegre, J. Pérez-Ruixo (2013)
Neutrophil Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal OxaliplatinClinical Pharmacokinetics, 52
T. Reichman, B. Cracchiolo, J. Sama, M. Bryan, J. Harrison, L. Pliner, L. Harrison (2005)
Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinomaJournal of Surgical Oncology, 90
W. Ceelen, Y. Nieuwenhove, S. Belle, H. Denys, P. Pattyn (2012)
Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian CancerAnnals of Surgical Oncology, 19
Y. Klaver, T. Hendriks, R. Lomme, H. Rutten, R. Bleichrodt, I. Hingh (2011)
Hyperthermia and Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis: An Experimental StudyAnnals of Surgery, 254
R. Alderden, M. Hall, T. Hambley (2006)
The Discovery and Development of CisplatinJournal of Chemical Education, 83
A. Campbell, S. Kalman, C. Jacobs (1983)
Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.Cancer treatment reports, 67 2
P. Reece, I. Stafford, J. Russell, M. Khan, P. Gill (1987)
Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 5 2
F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, Lindsey Torre, A. Jemal (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 68
P. Zingmark, M. Kågedal, M. Karlsson (2005)
Modelling a Spontaneously Reported Side Effect by Use of a Markov Mixed-Effects ModelJournal of Pharmacokinetics and Pharmacodynamics, 32
R. Cowan, R. O’Cearbhaill, O. Zivanovic, D. Chi (2017)
Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancerInternational Journal of Hyperthermia, 33
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Intraperitoneal chemoperfusion (IPEC) of cisplatin is a popular treatment for advanced ovarian cancer, typically under hyperthermia (HIPEC). The use of cisplatin under (H)IPEC is off-label, and the role of hyperthermia is unknown. The aim of this study was to characterize the pharmacokinetic/pharmacodynamic (PKPD) properties of cisplatin under (H)IPEC and to predict the optimal treatment regimen. Using a randomized design, data on intact cisplatin perfusate and plasma concentrations, leukocyte counts—a hematotoxicity marker—and serum creatinine—a nephrotoxicity marker—were collected from 50 patients treated with a combination of cytoreductive surgery (CRS) and either normothermic or hyperthermic IPEC of cisplatin dosed at 75, 100, and 120 mg/m2. The non-linear mixed effects modeling technique was used to construct the PKPD models. The PK of intact cisplatin was characterized by a two-compartment model. A semi-physiological myelosuppression model for the leukopenia was modified to account for the CRS-induced leukocytosis and the residual myelosuppression effect of neoadjuvant chemotherapy. The incidence and severity of nephrotoxicity were described by a discrete-time Markov model. Hyperthermia increased the absorption rate of cisplatin by 16.3% but did not show a clinically relevant impact on the investigated toxicities compared with normothermia. Leukopenia was not severe, but nephrotoxicity can become severe or life-threatening and was affected by the dose and IPEC duration. The model predicted that nephrotoxicity is minimal at a cisplatin dose of 75 mg/m2 with an IPEC duration of 1–2 h and an 1-h duration is favored for doses between 100 and 120 mg/m2.Graphical abstract[graphic not available: see fulltext]
"The AAPS Journal" – Springer Journals
Published: Jul 24, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.